A phase II study of vindesine in the treatment of esophageal carcinoma. Japanese Esophageal Oncology Group.
A phase II study of Vindesine for esophageal carcinoma was carried out cooperatively by 10 Japanese institutions. Fifty patients were enrolled in the study over a year and ten months. Four patients could not be evaluated because less than 4 weeks had elapsed since their preceding therapy. There were one complete remission and five partial remissions among the 46 remaining patients, a response rate of 13.0%. The patient experiencing the complete remission is still alive more than 24 months after treatment. The main side effects were depilation, anorexia, stomatitis and leukopenia. Thrombocytopenia and elevations of blood urea nitrogen and creatinine were not marked. There was no mortality connected with the administration of Vindesine. It was concluded that Vindesine is useful in the treatment of esophageal carcinoma as a single agent.
Lizuka
T
T
Department of Surgery, National Cancer Center Hospital, Tokyo.
Kakegawa
T
T
Ide
H
H
Ando
N
N
Watanabe
H
H
Mori
S
S
Sasaki
K
K
Takagi
I
I
Nashimoto
A
A
Ishida
K
K
D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction; D014751:Vindesine / Q000009:adverse effects / Q000627:therapeutic use*
D014751:Vindesine